

BIOTIME INC  
Form 8-K  
May 13, 2015

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): **May 11, 2015**

**BioTime, Inc.**

(Exact name of registrant as specified in its charter)

<b>California</b>	<b>1-12830</b>	<b>94-3127919</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**1301 Harbor Bay Parkway**  
**Alameda, California 94502**  
(Address of principal executive offices)

**(510) 521-3390**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

## Forward-Looking Statements

*Any statements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,” “believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in BioTime’s periodic reports filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and other filings that BioTime may make with the SEC. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, BioTime disclaims any intent or obligation to update these forward-looking statements.*

## Section 8 – Other Events

### Item 8.01 Other Events

On May 11, 2015, our subsidiary Cell Cure Neurosciences Ltd. received notice that it has been awarded a grant for 2015 of 6.24 million shekels (approximately \$1.61 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of Cell Cure’s lead product *OpRegen*<sup>®</sup>, a cell-based therapeutic product that consists of retinal pigment epithelial (RPE) cells for the treatment of the dry form of dry age-related macular degeneration (“dry AMD”). Cell Cure is now enrolling patients at Hadassah University Medical Center in Jerusalem, Israel, in a Phase I/IIa dose escalation safety and efficacy clinical study of *OpRegen*<sup>®</sup> for geographic atrophy, the severe stage of dry AMD. Under the terms of the grant award, Cell Cure is obligated to pay a 3.5% royalty to the OCS on revenues from *OpRegen*<sup>®</sup> up to an amount equal to 100% of the grant plus interest at a LIBOR rate.

## Section 9 – Financial Statements and Exhibits

### Item 9.01 Financial Statements and Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated May 13, 2015

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOTIME, INC.**

Date: May 13, 2015 By: /s/ Michael D. West  
Chief Executive Officer

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated May 13, 2015